today announced positive topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (UC). This press release features multimedia.

Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...

The features of chronic intestinal inflammation ... molecular mechanisms that underlie (non-)response to anti-TNFα therapy in ulcerative colitis. In this study we investigated endoscopic mucosal ...

Introduction Ulcerative colitis (UC) patients diagnosed with low ... regression was performed to create a multivariate risk prediction model based on endoscopic features. The model was then validated ...

Its role in disease monitoring is as an add-on test to Paediatric Ulcerative Colitis Activity Index and Paediatric ... Improved recognition of presenting features and judicious use of the screening, ...

Direct CD-related inflammation of the gallbladder is very unusual and the typical histological features of CD are rarely encountered ... no history of IBD against patients with diagnosed ulcerative ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo Itolizumab achieved key ...

Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...